A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: An open-label proof-of-concept study

Journal of the Peripheral Nervous System

Volumn 16, Issue 2, 2011, Pages 92-97

  Misbah, Siraj A ^a   Baumann, Andreas ^b   Fazio, Raffaella ^c   Dacci, Patrizia ^c   Schmidt, Dirk S ^d   Burton, Janet ^a   Sturzenegger, Matthias ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d CSL BEHRING GMBH   (Germany)

Author keywords

Disability; Intravenous immunoglobulin; Multifocal motor neuropathy; Muscle strength; Subcutaneous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HEADACHE; HEMATOMA; HUMAN; IMMUNOTHERAPY; INFLUENZA; INJECTION SITE EDEMA; INJECTION SITE PRURITUS; INJECTION SITE RASH; MALE; MOTOR NEUROPATHY; MOTOR PERFORMANCE; MULTICENTER STUDY; MULTIFOCAL MOTOR NEUROPATHY; MUSCLE STRENGTH; OPEN STUDY; ORCHITIS; PRIORITY JOURNAL; QUALITY OF LIFE; CLINICAL TRIAL; DEMYELINATING DISEASE; DISABILITY; DRUG EFFECT; MIDDLE AGED; POLYNEUROPATHY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; DEMYELINATING DISEASES; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MUSCLE STRENGTH; POLYNEUROPATHIES; QUALITY OF LIFE;

EID: 80052625612     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2011.00330.x     Document Type: Article

References (14)

1. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J (2000). The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20:94-100. (Pubitemid 30314313)
2. Dacci P, Riva N, Scarlato M, Andresen I, Schmidt D, Comi G, Fazio R (2010). Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report. Neurol Sci 31:829-831.
3. Eftimov F, Vermeulen M, de Haan RJ, van den Berg LH, van Schaik IN (2009). Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 14:93-100.
4. Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Bö ck A, Costa-Carvalho BT, Granert C, Haag S, Hernandez D, Kiessling P, Kus J, Matamoros N, Niehues T, Schmidt S, Schulze I, Borte M (2004). Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 114:936-942. (Pubitemid 39330270)
5. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J (2009). Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, singleblinded cross-over trial. Eur J Neurol 16:631-638.
6. Hogy B, Keinecke HO, Borte M (2005). Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ 6:24-29. (Pubitemid 40543267)
7. Joint Task Force of the EFNS and the PNS (2006). European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 11:1-8.
8. Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, van Doorn PA, Jacobs BC (2009). Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 66:597-603.
9. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N (2001). Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebocontrolled study. Brain 124:145-153. (Pubitemid 32055996)
10. Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, Ochs HD (2009). Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 158(Suppl. 1):51-59.
11. Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, Gardulf A, Eichmann F, Haag S, Massion C, Ochs HD (2006). Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 26:65-72. (Pubitemid 43112626)
12. Paternostro-Sluga T, Grim-Stieger M, Posch M, Schuhfried O, Fialka-Moser V (2008). Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med 40:665-671.
13. Sharrack B, Hughes RA (1999). The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 5:223-233. (Pubitemid 29405617)
14. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M (2005). Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2:CD004429.